O
ANIP icon

Ossiam’s ANI Pharmaceuticals ANIP Stock Holding History

Ossiam’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.65M Hold
47,400
– – 0.06% 126
2025
Q4 		$3.74M Hold
47,400
– – 0.07% 126
2025
Q3 		$4.34M Buy
+47,400
New +$3.87M 0.06% 223

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ossiam's ANIP Position: Q1 2026 in Review

Ossiam held its ANI Pharmaceuticals (ANIP) position steady in Q1 2026 at 47,400 shares worth $3.65M. The position accounts for 0.06% of the portfolio, ranked #126.

Ossiam first reported a position in ANIP in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.34M in Q3 2025. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Ossiam held 47,400 shares of ANI Pharmaceuticals worth $3.65M as of Q1 2026.
  • Ossiam left its ANI Pharmaceuticals share count unchanged in Q1 2026.
  • ANI Pharmaceuticals made up 0.06% of Ossiam's portfolio in Q1 2026, its #126 holding.
  • Ossiam first reported a position in ANI Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Ossiam's ANI Pharmaceuticals position peaked at $4.34M in Q3 2025.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Ossiam's 13F filing for Q1 2026, filed 14 May 2026.